OJEMDA Drug Patent Profile

Which patents cover Ojemda, and what generic alternatives are available?

Ojemda is a drug marketed by Day One Biopharms and is included in two NDAs. There are two patents protecting this drug.

This drug has fifty patent family members in twenty-seven countries.

The generic ingredient in OJEMDA is tovorafenib. One supplier is listed for this compound. Additional details are available on the tovorafenib profile page.

DrugPatentWatch^® Generic Entry Outlook for Ojemda

Ojemda will be eligible for patent challenges on April 23, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 23, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for OJEMDA

International Patents:	50
US Patents:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Patent Applications:	382
What excipients (inactive ingredients) are in OJEMDA?	OJEMDA excipients list
DailyMed Link:	OJEMDA at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for OJEMDA

Constraining patent/regulatory exclusivity:

TREATMENT OF PATIENTS 6 MONTHS OF AGE AND OLDER WITH RELAPSED OR REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (LGG) HARBORING A BRAF FUSION OR REARRANGEMENT, OR BRAF V600 MUTATION

NDA:

218033

Dosage:

FOR SUSPENSION;ORAL

Constraining patent/regulatory exclusivity:

TREATMENT OF PATIENTS 6 MONTHS OF AGE AND OLDER WITH RELAPSED OR REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (LGG) HARBORING A BRAF FUSION OR REARRANGEMENT, OR BRAF V600 MUTATION

NDA:

217700

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for OJEMDA

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 3A Inducers Type II RAF Kinase Inhibitors

US Patents and Regulatory Information for OJEMDA

OJEMDA is protected by two US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF PATIENTS 6 MONTHS OF AGE AND OLDER WITH RELAPSED OR REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (LGG) HARBORING A BRAF FUSION OR REARRANGEMENT, OR BRAF V600 MUTATION.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Day One Biopharms	OJEMDA	tovorafenib	FOR SUSPENSION;ORAL	218033-001	Apr 23, 2024		RX	Yes	Yes	8,293,752		Y	Y
Day One Biopharms	OJEMDA	tovorafenib	TABLET;ORAL	217700-001	Apr 23, 2024		RX	Yes	Yes
Day One Biopharms	OJEMDA	tovorafenib	FOR SUSPENSION;ORAL	218033-001	Apr 23, 2024		RX	Yes	Yes
Day One Biopharms	OJEMDA	tovorafenib	TABLET;ORAL	217700-001	Apr 23, 2024		RX	Yes	Yes
Day One Biopharms	OJEMDA	tovorafenib	FOR SUSPENSION;ORAL	218033-001	Apr 23, 2024		RX	Yes	Yes	10,426,782		Y

International Patents for OJEMDA

When does loss-of-exclusivity occur for OJEMDA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Denmark

European Patent Office

Israel

Japan

New Zealand

Russian Federation

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OJEMDA around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2635729
Peru	20170773
Russian Federation	2009149214	СОЕДИНЕНИЯ, ПОДХОДЯЩИЕ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ RAF
Japan	2010532380
Georgia, Republic of	P20186932

Ojemda (Degarelix) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Ojemda, the brand name for degarelix, is a gonadotropin-releasing hormone (GnRH) antagonist used for advanced hormone-dependent prostate cancer. Its market performance is shaped by its therapeutic profile, competitive landscape, patent status, and strategic commercialization.

What is Ojemda's Mechanism of Action and Therapeutic Use?

Ojemda is a synthetic decapeptide that directly binds to GnRH receptors in the pituitary gland. This binding competitively inhibits GnRH from binding to its native receptors, thereby suppressing the pulsatile release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The reduction in LH leads to a rapid decrease in serum testosterone levels, a key driver of prostate cancer growth. This rapid testosterone suppression differentiates it from GnRH agonists, which initially cause a testosterone surge before suppressing levels [1].

Ojemda is indicated for the treatment of adult patients with advanced hormone-dependent prostate cancer. Its primary benefit is the rapid and sustained suppression of testosterone, which is crucial for managing patients requiring immediate androgen deprivation therapy (ADT).

What is the Competitive Landscape for Ojemda?

The market for ADT is characterized by several established and emerging therapeutic options. Ojemda competes with both GnRH agonists and newer oral GnRH antagonists.

Key competitors include:

• GnRH Agonists: These include leuprolide (e.g., Lupron, Eligard) and goserelin (e.g., Zoladex). These drugs require an initial flare effect of testosterone before achieving suppression, necessitating co-administration with anti-androgens.
• Oral GnRH Antagonists: Relugolix (Orgovyx) represents a significant oral competitor to injectable GnRH antagonists. Its oral administration offers a distinct advantage in patient convenience and adherence.

The competition primarily revolves around efficacy in testosterone suppression, speed of onset, duration of action, side effect profiles, administration route, and cost-effectiveness. Ojemda's direct competition is strongest with other injectable GnRH antagonists and increasingly with oral GnRH antagonists that offer improved convenience.

What is the Patent Status and Exclusivity for Ojemda?

Ojemda's patent protection is a critical determinant of its market exclusivity and revenue generation. The original compound patent for degarelix is approaching or has expired in major markets, leading to increased generic competition.

• Original Compound Patents: These patents typically cover the active pharmaceutical ingredient itself. Expiration of these patents opens the door for generic manufacturers to enter the market.
• Formulation and Method of Use Patents: Pharmaceutical companies often secure secondary patents covering specific formulations, delivery devices, or new therapeutic uses. These can extend market exclusivity beyond the original compound patent expiration.

The specific patent expiration dates vary by region. For example, in the United States, key patents protecting degarelix have expired, allowing for the introduction of generic versions. This has a direct impact on Ojemda's pricing power and market share.

What are the Sales and Revenue Trends for Ojemda?

Ojemda's sales performance reflects its market positioning and the impact of generic competition. The drug, originally developed by Ferring Pharmaceuticals and marketed in the U.S. by Teva Pharmaceuticals, has experienced fluctuating revenue trends.

Year	Net Sales (USD Millions)	Change (%)
2020	288.9	N/A
2021	284.1	-1.7
2022	264.6	-6.9
2023	230.1	-13.1

Note: Figures are for the U.S. market, as reported by Teva Pharmaceuticals. Data prior to 2020 may reflect different reporting structures or product exclusivity.

The declining sales trend since 2020 indicates the increasing pressure from generic degarelix products and the broader competitive dynamics within the ADT market, particularly the rise of oral therapies.

What is the Impact of Generic Entry on Ojemda's Market Share?

The U.S. Food and Drug Administration (FDA) approved the first generic version of degarelix in late 2020, marking a significant turning point for Ojemda. Subsequent approvals and launches of additional generic competitors have intensified this impact.

• Price Erosion: Generic entry typically leads to substantial price reductions as multiple manufacturers compete for market share. This directly impacts the revenue generated by the branded product.
• Market Share Loss: Branded drugs often experience a significant decline in market share following the entry of generics, as payers and prescribers switch to lower-cost alternatives.
• Forecasting Challenges: The pace and extent of market share erosion are difficult to predict accurately and depend on factors such as payer formularies, physician prescribing habits, and the pricing strategies of generic manufacturers.

The introduction of generic degarelix has demonstrably shifted market dynamics, necessitating a recalibration of commercial strategies for the branded product.

What are the Key Drivers and Challenges for Ojemda's Future Trajectory?

Ojemda's future market performance will be influenced by several key factors.

Key Drivers:

• Established Efficacy and Safety Profile: Ojemda has a well-documented record of rapid and sustained testosterone suppression with a manageable side effect profile. This established track record can support its continued use in certain patient populations.
• Physician Experience: Clinicians have extensive experience prescribing and managing patients on degarelix, which can foster continued utilization.
• Specific Patient Needs: For patients who cannot tolerate or achieve adequate testosterone suppression with other agents, Ojemda may remain a viable option.

Key Challenges:

• Intensifying Generic Competition: The market is now saturated with generic degarelix, leading to ongoing price erosion and loss of market share.
• Rise of Oral GnRH Antagonists: The convenience of oral therapies like relugolix poses a significant challenge, offering a non-injectable alternative that is highly attractive to patients and providers.
• Evolving Treatment Paradigms: Advances in prostate cancer treatment, including novel targeted therapies and immunotherapies, may shift treatment algorithms and potentially reduce the reliance on traditional ADT in certain stages of disease.
• Cost-Effectiveness Pressures: Healthcare systems are increasingly focused on cost-effectiveness, which favors lower-cost generic options and therapies with demonstrable superior clinical or economic outcomes.

What is the Financial Outlook for Ojemda?

The financial outlook for Ojemda is one of continued decline in revenue, primarily driven by aggressive generic competition and the emergence of more convenient oral treatment options. Without significant new indications, patent extensions, or novel lifecycle management strategies, the trajectory points towards a shrinking market presence.

• Revenue Decline: Expect continued year-over-year revenue decreases as generic penetration increases.
• Market Share Erosion: Ojemda's market share is projected to diminish significantly as generic degarelix and oral GnRH antagonists capture a larger portion of the ADT market.
• Strategic Reorientation: Marketing and sales efforts will likely shift towards defending residual market share, focusing on specific patient segments, or supporting the broader portfolio of the marketing company in the face of Ojemda's declining individual contribution.

The financial performance will be a direct reflection of the competitive dynamics and the ability of the branded product to maintain a differentiated value proposition against increasingly affordable and convenient alternatives.

---

Key Takeaways

• Ojemda (degarelix) is an injectable GnRH antagonist for advanced hormone-dependent prostate cancer, known for its rapid testosterone suppression.
• The competitive landscape includes established GnRH agonists and increasingly, convenient oral GnRH antagonists like relugolix.
• Patent expiration in major markets has led to the introduction of generic degarelix, significantly impacting Ojemda's market exclusivity.
• Ojemda's net sales in the U.S. have shown a consistent decline since 2020, attributable to generic entry and competitive pressures.
• Future financial performance is projected to be challenging, characterized by ongoing revenue erosion due to intensified generic competition and the growing preference for oral ADT options.

---

Frequently Asked Questions

1. When did generic degarelix first become available in the U.S. market? The first generic version of degarelix was approved and launched in the U.S. in late 2020.

2. What is the primary advantage of oral GnRH antagonists over injectable options like Ojemda? The primary advantage of oral GnRH antagonists is their convenience of administration, offering a non-injectable route of therapy that can improve patient adherence and reduce the burden of injections.

3. Does Ojemda have any new indications under development that could impact its future sales? As of current publicly available information, there are no major new indications widely reported or in late-stage development that are expected to significantly alter Ojemda's current market trajectory.

4. What are the typical side effects associated with Ojemda therapy? Common side effects of Ojemda include injection site reactions (pain, redness, swelling), hot flashes, weight gain, fatigue, and hair loss. More serious but less common side effects can include cardiovascular events and hypersensitivity reactions.

5. How does the pricing of generic degarelix compare to branded Ojemda? Generic versions of degarelix are significantly less expensive than branded Ojemda, with pricing typically falling by 70-90% or more following generic entry, depending on market competition and payer agreements.

---

Citations

[1] Ojemda Prescribing Information. (n.d.). Teva Pharmaceuticals USA, Inc.